VedaBio: Frédéric Sweeney, Maurice Exner
Frédéric Sweeney has been appointed as president and CEO of VedaBio. Previously, he was executive chairman, president, and chief operating officer the San Diego-based CRISPR firm. Prior to joining VedaBio, he held executive roles at MeMed Diagnostics, BioMérieux, Versant Ventures, Northern Biologics, and T2 Biosystems.
Maurice Exner is taking over for Sweeney as VedaBio's COO. He comes to the firm from Sherlock Biosciences, where he was CSO. Prior to that, he was VP of R&D, assay development, and clinical affairs at Hologic. He also worked in product development/M&A integration at Abbott Point of Care and was R&D manager at Quest Diagnostics. Exner holds a BSc in microbiology from the University of Regina and a PhD in microbiology from the University of British Columbia.